Effects of letrozole, an aromatase inhibitor, on androgen-dependent telomerase activation
| . | Relative telomerase activity (n = 4) Letrozole concentration . | |
|---|---|---|
| 0 . | 1 μM . | |
| Methyltrienolone (R1881) concentration | ||
| 0 | 100% | 116 ± 9.5%† |
| 0.5 μM | 153 ± 3.8%* | 108 ± 9.1%† |
| . | Relative telomerase activity (n = 4) Letrozole concentration . | |
|---|---|---|
| 0 . | 1 μM . | |
| Methyltrienolone (R1881) concentration | ||
| 0 | 100% | 116 ± 9.5%† |
| 0.5 μM | 153 ± 3.8%* | 108 ± 9.1%† |
Telomerase activity of cultured lymphocytes is expressed as relative telomerase activity (considering telomerase activity of each donor in the absence of hormones as reference activity). Letrozole is an aromatase (CYP19) inhibitor, preventing androgens from being converted into estrogen. Normal peripheral blood lymphocytes from 4 healthy subjects were cultured for 3 days in two separate experiments each.
P < .05 in Kruskal-Wallis test; P < .05 when compared to condition without R1881 and letrozole.
Difference not statistically significant in comparison to control (no drugs added).